N2OFF signs definitive agreement to acquire MitoCareX Bio in stock-cash deal

Nexentis Technologies Inc.

N2OFF will pay $700,000 cash to SciSparc for 4,961 shares and issue common stock totaling 40% of fully diluted capital to all sellers.
Sellers eligible for milestone-based issuance of up to 25% additional common stock and 30% of N2OFF financing proceeds capped at $1.6M over 5 years.
N2OFF commits initial $1M investment in MitoCareX plus ongoing funding; MitoCareX becomes wholly-owned subsidiary upon closing.
Transaction subject to N2OFF stockholder approval; board members Amitay Weiss and Liat Sidi also serve on SciSparc board (related party).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.